TenCure is a biopharmaceutical company developing personalized oncology therapeutics for epithelial solid tumors associated with skin, colon, and pancreatic cancer. TenCure is establishing a first-in-class, diverse pipeline of oncology therapies, with a specific focus on niche markets with unmet needs.

The company has identified a new mechanism of action by which the insulin signaling pathway affects cancer formation and progression. TenCure is developing inhibitory agents within the insulin signaling pathway that deactivate these targets. The drug candidates have the potential to inhibit cancer cell proliferation, eradicate tumors, and suppress malignant tumor progression.

TenCures drug candidates provide the basis for the development of novel cancer therapies addressing various solid cancer indications that are resistant to current treatment modalities. The companys management team has developed a plan aimed at shortening the development path, reducing costs, and increasing the likelihood of bringing a mature product to advanced clinical trials within three years.